Oxtex is a University of Oxford spinout developing anisotropic self‑inflating tissue expanders. Led by CEO David Jackson, the company is developing a product range based on hydrogel technology that provides novel soft tissue expansion solutions across reconstructive surgery and dentistry. It has completed a £150k funding round backed by a syndicate of LBA angels. Oxtex intends to use the new capital to further develop its technology and to gain medical approvals in the European Union (MHRA) and the United States (FDA). The company also plans to establish a small clean‑room manufacturing facility for production of clinical devices and to initiate clinical trials. Oxtexs develops novel and intelligent hydrogel self-inflating tissue expanders for scar reconstruction and the treatment of congenital craniofacial conditions and limb deformities. The devices are designed to allow surgeons to accurately and predictably control the direction, timing, and rate of in vivo expansion, reducing the risk of soft tissue damage and associated complications. Incorporated in spring 2011 as a spinout from the University of Oxford, the company is based in Oxford, UK and is led by CEO David Jackson. Oxtexs is currently establishing clean-room manufacturing facilities to scale up production. The company is in the process of setting up clinical trials. It raised £500k in seed funding and appointed Nicholas Edwards as Chairman.

Total raised

$1M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2012